- Home
- EVMN vs SLGL Comparison
EVMN vs SLGL Comparison
Compare EVMN & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EVMN | SLGL |
|---|---|---|
| Founded | 2020 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 241.3M | 218.9M |
| IPO Year | 2025 | 2016 |
Fundamental Metrics
Financial Performance| Metric | EVMN | SLGL |
|---|---|---|
| Price | $5.89 | $70.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 3 |
| Target Price | $22.33 | ★ $152.50 |
| AVG Volume (30 Days) | ★ 816.5K | 34.4K |
| Earning Date | 11-07-2026 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.23 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 85.71 | N/A |
| 52 Week Low | $6.02 | $28.81 |
| 52 Week High | $33.20 | $97.97 |
Technical Indicators
Market Signals| Indicator | EVMN | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 17.99 | 49.32 |
| Support Level | N/A | $69.09 |
| Resistance Level | $13.35 | $80.53 |
| Average True Range (ATR) | 0.47 | 4.54 |
| MACD | -0.05 | 0.52 |
| Stochastic Oscillator | 1.31 | 56.22 |
Price Performance
Historical ComparisonAbout EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.